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Background: The Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool is intended to be used in the
design phase of trials to help investigative teams design trials in-line with their purpose. Our team applied this tool
to an ongoing trial (BLISTER) to determine whether the initial suggestion among some team members that the trial
could be described as largely pragmatic was the consensus.
Methods: Each of the six members of the BLISTER trial team was sent a blank PRECIS wheel to independently
complete. The results obtained were averaged and plotted on a single PRECIS wheel to illustrate the degree of
pragmatism of the trial.
Results: The trial team found that the design of the trial was closest to the pragmatic end of the pragmatic-
explanatory continuum. The strongest consensus was found on the ‘flexibility of the comparison intervention’ and
‘practitioner adherence’ domains (SD=13). The trial team appeared to disagree most on the ‘eligibility criteria’ (SD= 35)
and ‘participant compliance’ (SD= 31) domains, although the large standard deviations were a result of a single outlier
in the two domains.
Conclusion: The PRECIS tool can be used to retrospectively determine the pragmatism of a trial provided enough
expertise and information on the trial is available. Illustrating the design of a trial on the PRECIS wheel can help research
users more easily identify studies of interest. We hope our recommendations for applying this useful tool will
encourage others to consider using it when designing, conducting and reporting studies.
Trial registration: Current Controlled Trials ISRCTN13704604
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Pragmatic and explanatory trials
Clinical trials are sometimes described as being either prag-
matic or explanatory. A pragmatic clinical trial is designed
to test treatment effectiveness under real life conditions. To
achieve this, pragmatic trials are designed to mirror current
clinical practice by using active comparators and by permit-
ting flexibility in the way interventions are used. Typically a
wide range of participants with co-morbidities and* Correspondence: hywel.williams@nottingham.ac.uk
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reproduction in any medium, provided the orcompliance are included that more readily reflect clinical
practice to increase the external validity or generalizability
of results. By contrast, explanatory clinical trials are more
restrictive and address treatment efficacy under ideal condi-
tions. Explanatory trials typically recruit a narrow spectrum
of patients who are likely to respond to therapy, trial treat-
ments are likely to be standardised and closely controlled,
and follow-up may be much more intensive than that
undertaken in clinical practice. Explanatory trials typically
answer the question ‘can this treatment work?’ whereas
pragmatic trials are more geared towards answering the
question ‘does this treatment work in clinical practice?’.
This pragmatic-explanatory dichotomy is over-simplisticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cept of a pragmatic-explanatory continuum exists [1,2].
The pragmatic-explanatory continuum indicator summary
wheel
The Pragmatic-Explanatory Continuum Indicator Sum-
mary (PRECIS) wheel is a relatively new and useful tool
for determining the position of a trial’s design in the
pragmatic-explanatory continuum [2]. It is intended to
be used in the design phase of trials to help determine
whether the trial design fits with its intended purpose
and perspective. The wheel assesses 10 key characteris-
tics of a trial: eligibility criteria, flexibility of the experi-
mental and comparison interventions, practitioner
expertise of the experimental and comparison interven-
tions, follow-up intensity, primary outcome, participant
compliance, practitioner adherence and analysis of the pri-
mary outcome. A detailed description of each of these is
given in the paper by Thorpe et al. [2]. The characteristics
are represented by 10 spokes of a wheel (see Figure 1),
each of which represents a pragmatic-explanatory con-
tinuum with the most pragmatic design marked on the
rim and the most explanatory design at the centre. By
mapping the features of a trial’s design onto each of these
10 domains, readers can gain an immediate visual sense of
the extent to which a trial as a whole and, in particular,Participant
Compliance
Outcomes
Follow-up
Intensity
Practitioner
Expertise
(Comparison)
Flexibility  of  the
Comparison
Intervention
Figure 1 The Pragmatic-Explanatory Continuum Indicator Summary (which domains are suggestive of a pragmatic or explana-
tory perspective.
Whilst the PRECIS tool seems to have good potential
for practical use, little has been written on its application
for those designing and conducting clinical trials. The
PRECIS tool was recently used by a team designing a
trial of a pain-coping skills training intervention for
patients scheduled for knee arthroplasty [3]. In that
study, the authors reported that the tool aided discus-
sion on some trial design areas that may not have other-
wise been discussed, and it helped the team reach a
stronger consensus on the design of the trial. Another
group used the PRECIS tool to estimate the degree to
which randomised controlled trials included in two sys-
tematic reviews were predominantly pragmatic or ex-
planatory [4].
In a study by Glasgow et al., nine reviewers each ap-
plied the PRECIS wheel to three weight loss studies with
each PRECIS domain split into a five-point scoring sys-
tem [5]. The authors then reported the average score in
each domain and plotted these onto a single PRECIS
wheel for each of the three trials. Categorising each do-
main into a limited number of points removes the con-
tinuous element of the PRECIS tool but if a sufficient
number of points are used (for example, at least 10)
then the loss of information should be minimal.Eligibility 
Criteria
Flexibility of the 
Experimental 
Intervention
Primary
Analysis
Practitioner
Adherence
Practitioner
Expertise
(Experimental)
PRECIS) wheel [2].
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plication of the PRECIS tool easier.
A study by Tosh et al. also used the five-point scoring
system described above and applied it to mental health
trials [6]. The scores on each wheel were summed onto
a 0 to 50 scale, effectively reducing the multidimensional
PRECIS tool to a single dimension. The authors inter-
preted a trial scoring 0 to 30 as explanatory and more
than 35 as pragmatic, with the interim representing trials
which ‘balance pragmatic and explanatory domains’ [6].
Such an interpretation does not acknowledge the existence
of the pragmatic-explanatory continuum, meaning that
two trials classified as pragmatic cannot be distinguished
even if one may be considerably more pragmatic than the
other.
In this descriptive study, we describe the use of the
PRECIS tool in helping to resolve debate within the trial
team on whether an ongoing clinical trial of two drug
treatments in a rare blistering skin disease was more
pragmatic or explanatory. We also provide practical sug-
gestions on how best to use the PRECIS tool in such a
context.Table 1 Additional guidance for scoring the 10 PRECIS
domains in the context of the BLISTER trial
PRECIS domain Description in the context of BLISTER
Eligibility criteria Are most patients who would normally be
treated included in the trial? How strict
are the criteria?
Follow-up intensity How similar to normal practice is the
patient follow-up?
Primary outcomes Would those considered to be a
treatment success in the trial (for
example, three or fewer blisters present at
six weeks of follow-up) also be considered
a treatment success in practice?
Method of analysing the
primary endpoints
Are there many exclusions
from the analysis? How
inclusive is the definition
of per-protocol?
Doxycycline and
prednisolone flexibility
Can trial treatments be altered
during follow-up or are
patients expected to stay on
the prescribed dose?
Is this any different to normal practice?
Practitioner expertise
on doxycycline and
prednisolone
Are patients seen by specialists?
Would they normally be seen by,
for example, general practitioners?
Participant compliance How closely is this measured?
Are there interventions made
to maintain or improve compliance?
Practitioner adherence
to the protocol
Is the study concerned whether
investigators ‘customise’ the trial
to suit their own setting? Are all
investigators expected to
treat patients in the same way?The bullous pemphigoid steroids and tetracyclines study
The bullous pemphigoid steroids and tetracyclines
study (BLISTER, ISRCTN13704604) is a randomised
non-inferiority trial that seeks to determine whether
doxycycline (200 mg/day) is non-inferior to prednisol-
one (0.5 mg/kg/day) in the treatment of bullous pem-
phigoid. Doxycycline is unlikely to be more effective
than oral steroids for inducing remission and control-
ling blister formation in this autoimmune blistering
disease, but it is likely to have some degree of efficacy
and is probably much safer in the long-term than oral
steroids [7,8]. The latter can, in an extreme scenario, lead
to premature death in the predominantly elderly popula-
tion that develop pemphigoid. Non-inferiority will be con-
cluded in this trial if both the short-term control of
pemphigoid in the doxycycline arm is not worse than that
in the prednisolone arm by more than the pre-specified
non-inferiority margin and if doxycycline is superior in
terms of long-term safety.
Throughout the development of the BLISTER trial,
members of the trial management group (TMG)
debated whether BLISTER could be considered to be a
pragmatic or explanatory trial. While some members
considered that the trial was more towards the prag-
matic end of the spectrum, others were less certain
given the participant inclusion criteria and the standar-
dised initial dosage of the trial treatments. In order to
reach a consensus, it was decided to use the PRECIS
tool to retrospectively determine the pragmatism of
the trial’s design.Methods
Applying the PRECIS wheel to BLISTER
The TMG for BLISTER consists of the trial manager, two
clinicians with clinical expertise in pemphigoid, a clinician
with expertise in trial design and two statisticians. Blank
PRECIS wheels, approximately 15 cm in diameter, to-
gether with the paper by Thorpe et al. [2] containing
detailed instructions for completing the wheel were sent to
the six TMG members for completion. All members com-
pleted their wheels independently apart from the two sta-
tisticians, who completed a single wheel together. Some
TMG members were unable to complete the wheel using
only the guidance given in the paper by Thorpe et al. [2]
and so extra guidance was provided on scoring each do-
main in the context of the trial (see Table 1) rather than in
the more general context given in their paper. For example,
Thorpe et al. do not discuss the primary analysis domain
in the context of a non-inferiority primary endpoint. It is
widely accepted that such an endpoint should be analysed
on both intention-to-treat (pragmatic) and per-protocol
(explanatory) populations [9], which implies that a non-in-
feriority trial cannot lie at either extremity of the ‘primary
analysis’ continuum. In our study, we scored this domain
by considering not only the inclusiveness of the per-
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also the method of analysis for the co-primary superiority
safety outcome. Such co-primary outcomes are often
present in non-inferiority studies and must be considered
with equal importance.
In addition to this extra guidance, members were also
given the option of scoring each domain on a 0 (most
explanatory) to 10 (most pragmatic) scale if this was eas-
ier. Scores obtained from this method were then mapped
onto a wheel by the person collating the results.
Once each wheel had been completed, the distance of
the score in each domain from the most extreme ex-
planatory end of the spectrum (the centre) was mea-
sured and transformed into a percentage of the total
length of a spoke. If the scoring was given on a 0 to 10
scale, percentages were calculated by simply multiplying
by 10. The transformed results were then averaged and
plotted on a single PRECIS wheel together with the
minimum (most explanatory) and maximum (most prag-
matic) scores in each domain.Results
The scores given in each domain of the PRECIS wheel
from each TMG member are shown in Table 2. The over-
all results, calculated as the mean score in each domain,
are shown in Figure 2 along with the most explanatory
and most pragmatic scores given by the TMG.Table 2 Summary of scores given by BLISTER trial
management group members for each domain of the
PRECIS wheel
Domain Score Mean score
(SD)
Median
score
A B C Da Ea
Eligibility criteria 74 83 0 80 50 57 (35) 74
Flexibility of the
experimental
intervention
64 86 85 50 100 77 (20) 85
Practitioner expertise
(experimental)
45 100 92 100 90 85 (23) 92
Flexibility of the
comparison
intervention
64 80 80 50 60 67 (13) 64
Practitioner expertise
(comparison)
45 98 90 100 100 87 (24) 98
Follow-up intensity 61 89 50 100 70 74 (20) 70
Outcome 79 58 75 100 100 82 (19) 79
Participant compliance 86 84 20 100 80 74 (31) 84
Practitioner adherence 59 77 70 50 80 67 (13) 70
Primary analysis 74 92 20 50 80 63 (29) 74
A to E represent the members of the trial management group. Scores were
transformed onto a 0 to 100 scale with 0 representing the most extreme
explanatory end of each domain and 100 representing the most extreme
pragmatic end. aD and E scored the pragmatism of the trial on each domain
out of 10 rather than opting to complete a PRECIS wheel.As Figure 2 shows, the mean score for each domain is
closer to the rim, or the pragmatic end, of the PRECIS
wheel than the centre, or explanatory end. Table 2 shows
that consensus on the pragmatism of the trial among all
TMG members was present in only a few domains. For
example, the standard deviation of the scores is relatively
low (less than 15) on the ‘practitioner adherence’ and
‘flexibility of the comparison intervention’ domains. In
most other domains, the large standard deviations are due
to outliers. For example, the ‘participant compliance’, ‘eligi-
bility criteria’ and ‘primary analysis’ arms were considered
by one member of the TMG to be almost totally explana-
tory in contrast to the rest of the group. A number of
domains were scored at the pragmatic extremity, suggesting
that the trial could be considered entirely true to clinical
practice in those domains.Discussion
Although we have successfully managed to identify BLIS-
TER as a predominantly pragmatic trial, a number of
issues concerning how the PRECIS wheel is completed
have become apparent.
Asking only the members of a TMG to independently
complete the PRECIS wheel has its advantages and dis-
advantages. First, independent completion of the wheel
ensures results are not influenced by other TMG mem-
bers. Furthermore, the members of a TMG are expected
to be fully familiar with the trial and are arguably in the
best position to determine its pragmatism; however, they
may have a vested interest in calling the trial pragmatic
or explanatory, which could influence their results. To
reduce such bias, the members of the data monitoring
or trial steering committees, who are independent to the
trial but also have enough knowledge on both current
clinical practice and the trial itself, could also be asked
to complete the wheel and have their results combined
and compared with those from the TMG.
One of the main problems encountered during the
completion of the wheel for the BLISTER trial was that
some TMG members, depending on their expertise,
found it difficult to complete certain domains. For ex-
ample, the statisticians, with limited knowledge of the
current clinical practice for treating bullous pemphig-
oid, found it difficult to complete the practitioner ex-
pertise domains. This inevitably led to guesswork but
was unlikely to strongly affect the overall result since
three of the other TMG members completing the wheel
were expert dermatologists and so would provide more
accurate scores. By contrast, some of the clinicians
found the primary analysis domain tricky since it poses
a more statistical than clinical question. Thus it is clear
that composition and balance of the team may influence
the end result to some extent.
Eligibility
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Flexibilityof the
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Intervention
Primary
Analysis
Practitioner
Adherence
Participant
Compliance
Outcomes
Follow-up
Intensity
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Comparison
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Figure 2 PRECIS wheel showing the mean of the scores given by BLISTER trial management group members (solid line). Also presented
are the most explanatory scores (inner line) and most pragmatic scores (outer line) given in each domain. Scores were plotted on the wheel
using a simple picture editing program.
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highlight any inconsistencies or outliers arising through
guess work, as described above, or by conflicting view-
points. There is an argument, therefore, for following up
independent scoring of domains with team discussions be-
tween those involved in the scoring to resolve misunder-
standings and disagreements and to reach a clearer
consensus, rather than relying on only one mean score.
In this study we used the PRECIS tool to retrospectively
determine the pragmatism of a clinical trial. It should be
pointed out that this is not the intended use of the tool,
and in certain situations problems can arise from using
the tool in this way. For example, if a researcher wishes to
retrospectively complete a PRECIS wheel for a particular
trial and the only available source of information is the
trial report then, despite reporting standards such as the
Consolidated Standards of Reporting Trials and its prag-
matic trial extension [10], there may be inadequate report-
ing of some of the PRECIS domains to enable the
researcher to complete the wheel fully. Tosh and collea-
gues suggested that domains with no information available
in the trial protocol or elsewhere should be scored at the
explanatory extremity [6]. Such an approach may be in-
appropriate since it biases poorly described trials towards
the explanatory end of the spectrum even if in reality theywere very pragmatic in their design. In our study, all those
who completed a wheel were fully familiar with the trial
and its design, and a full trial protocol had already been
developed, therefore problems regarding poorly described
domains were not of concern.
Conclusions
Identifying which trials are more pragmatic than others
is important since pragmatic trials often have more
generalizable results. Classifying a trial as pragmatic
could have important implications for funders, policy
makers, clinicians, patients and those who conduct sys-
tematic reviews and guidelines. The PRECIS wheel is a
useful tool for determining the extent of pragmatism of
a trial and we recommend that it be more widely used,
particularly in the design stage. Furthermore, we suggest
that completed wheels are included in the trial protocol
or trial report to enable researchers to quickly identify
trials with designs more suited to their area of interest.
When using the PRECIS wheel to design a trial, we
recommend following the methods used by Riddle et al.
[3], who showed how use of the PRECIS wheel can help
researchers reach a consensus on trial design. In their
paper, the team first independently completed separate
wheels based on the initial design of their trial and each
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the scores in each domain were then discussed in detail
and a final wheel was then produced by each team mem-
ber. The variability in the scores given for the final wheel
was shown to be lower than that for the initial and ideal
wheels showing stronger agreement had been reached.
If the trial has already commenced, we recommend that
the PRECIS wheel should also be completed by members
of independent committees to the trial as well as members
of the trial management group in order to minimise bias.
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